Skip to main content
SpringerLink
Log in

Diagnostic and Prognostic Biomarkers in Melanoma: Current State of Play

  • Chapter
  • First Online:
Book cover Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma

Part of the book series: Current Clinical Pathology ((CCPATH))

Abstract

Melanoma is the most deadly skin cancer. The incidence and mortality rates of this tumor have been increasing over the last number of decades. Besides clinical and histopathological characteristics (i.e., anatomic site and subtype of the primary tumor, Breslow thickness, ulceration, vascular invasion, mitotic index), an increasing variety of molecular markers have been identified, providing the possibility of a more detailed diagnostic and prognostic categorization of melanoma. Recently published gene expression and proteomic profiling data indicate new candidate molecules involved in melanoma pathogenesis, which are currently validated. This ongoing process of biomarker identification and validation is resulting in a rapidly changing molecular view of cutaneous melanoma, which holds the promise to improve our diagnostic and prognostic classification systems, as well as identifying therapeutic targets. In this chapter, we provide a comprehensive overview of the currently known serological and immunohistochemical biomarkers in melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35:433–44.

    Article  PubMed  Google Scholar 

  2. Niezabitowski A, Czajecki K, Rys J, Kruczak A, Gruchała A, Wasilewska A, Lackowska B, Sokołowski A, Szklarski W. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol. 1999;70:150–60.

    Article  PubMed  CAS  Google Scholar 

  3. Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res. 2005;65:11185–92.

    Article  PubMed  CAS  Google Scholar 

  4. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA, Rodriguez-Peralto JL. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol. 2004;164: 193–203.

    Article  PubMed  CAS  Google Scholar 

  5. Janku F, Novotny J, Julis I, Julisova I, Pecen L, Tomancova V, Kocmanova G, Krasna L, Krajsova I, Stork J, Petruzelka L. KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res. 2005;15:251–6.

    Article  PubMed  CAS  Google Scholar 

  6. Cruz J, Reis-Filho JS, Silva P, Lopes JM. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology. 2003;65:72–82.

    Article  PubMed  CAS  Google Scholar 

  7. Kraehn GM, Utikal J, Udart M, Greulich KM, Bezold G, Kaskel P, Leiter U, Peter RU. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer. 2001;84:72–9.

    Article  PubMed  CAS  Google Scholar 

  8. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, Pfeifer A, Fässler R, Bosserhoff AK. Down-regulation of CYLD expression by snail promotes tumor progression in malignant melanoma. J Exp Med. 2009;206:221–32.

    Article  PubMed  CAS  Google Scholar 

  9. Udart M, Utikal J, Krahn GM, Peter RU. Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia. 2001;3:245–54.

    Article  PubMed  CAS  Google Scholar 

  10. Jovanovic B, Kröckel D, Linden D, Nilsson B, Egyhazi S, Hansson J. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol. 2008;128:2696–704.

    Article  PubMed  CAS  Google Scholar 

  11. Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H, Ullrich A. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res. 2008;14: 5188–97.

    Article  PubMed  CAS  Google Scholar 

  12. Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, Kamino H, Spira JG, Kopf AW, Houghton A, Cordon-Cardo C, Osman I. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst. 2002;94:1803–6.

    PubMed  CAS  Google Scholar 

  13. Wang Y, Dai DL, Martinka M, Li G. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin Cancer Res. 2007;13:4111–6.

    Article  PubMed  CAS  Google Scholar 

  14. Ugurel S, Houben R, Schrama D, Voigt H, Zapatka M, Schadendorf D, Bröcker EB, Becker JC. Micro­phthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res. 2007;13:6344–50.

    Article  PubMed  CAS  Google Scholar 

  15. Mihic-Probst D, Mnich CD, Oberholzer PA, Seifert B, Sasse B, Moch H, Dummer R. p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer. 2006;118:2262–8.

    Article  PubMed  CAS  Google Scholar 

  16. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol. 2005;23: 1473–82.

    Article  PubMed  CAS  Google Scholar 

  17. Roesch A, Becker B, Meyer S, Hafner C, Wild PJ, Landthaler M, Vogt T. Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma. Mod Pathol. 2005; 18:565–72.

    Article  PubMed  CAS  Google Scholar 

  18. Mikhail M, Velazquez E, Shapiro R, Berman R, Pavlick A, Sorhaindo L, Spira J, Mir C, Panageas KS, Polsky D, Osman I. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res. 2005;11:5153–7.

    Article  PubMed  CAS  Google Scholar 

  19. Lin H, Wong RP, Martinka M, Li G. Loss of SNF5 expression correlates with poor patient survival in melanoma. Clin Cancer Res. 2009;15:6404–11.

    Article  PubMed  CAS  Google Scholar 

  20. Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res. 2000;6:3614–20.

    PubMed  CAS  Google Scholar 

  21. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol. 2001;195:530–6.

    Article  PubMed  CAS  Google Scholar 

  22. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A, Melanoma Group of the European Organization for Research and Treatment of Cancer. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006;98:472–82.

    Article  PubMed  CAS  Google Scholar 

  23. Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guerry D. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048–56.

    Article  PubMed  Google Scholar 

  24. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, Suter L. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol. 2001;145:203–9.

    Article  PubMed  CAS  Google Scholar 

  25. Fujimoto A, Takeuchi H, Taback B, Hsueh EC, Elashoff D, Morton DL, Hoon DS. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res. 2004;64:2245–50.

    Article  PubMed  CAS  Google Scholar 

  26. Fecker LF, Geilen CC, Tchernev G, Trefzer U, Assaf C, Kurbanov BM, Schwarz C, Daniel PT, Eberle J. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol. 2006;126:1366–71.

    Article  PubMed  CAS  Google Scholar 

  27. Tas F, Duranyildiz D, Argon A, et al. Serum bcl-2 and survivin levels in melanoma. Melanoma Res. 2004;14:543–6.

    Article  PubMed  CAS  Google Scholar 

  28. Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol. 2003;162:1951–60.

    Article  PubMed  Google Scholar 

  29. Wu H, Barusevicius A, Babb J, et al. Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. J Cutan Pathol. 2005;32:125–30.

    Article  PubMed  CAS  Google Scholar 

  30. Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res. 2005;11:8606–14.

    Article  PubMed  CAS  Google Scholar 

  31. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20:2530.

    Article  PubMed  CAS  Google Scholar 

  32. Nishizawa A, Nakanishi Y, Yoshimura K, et al. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. Cancer. 2005;103:1693–700.

    Article  PubMed  CAS  Google Scholar 

  33. Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo GM. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol. 2004;17:990–7.

    Article  PubMed  CAS  Google Scholar 

  34. Saalbach A, Wetzel A, Haustein UF, Sticherling M, Simon JC, Anderegg U. Interaction of human Thy-1 (CD90) with the integrin αvß3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene. 2005;24: 4710–20.

    Article  PubMed  CAS  Google Scholar 

  35. Redondo P, Lloret P, Idoate M, Inoges S. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol. 2005;30:541–5.

    Article  PubMed  CAS  Google Scholar 

  36. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999;30:339–44.

    Article  PubMed  CAS  Google Scholar 

  37. Luongo V, Pirozzi G, Caraco C, Errico S, de Angelis F, Celentano E, Paino F, Chiofalo MG, Luongo M, Mozzillo N, Lombardi ML. HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma. Tissue Antigens. 2004;64:84–7.

    Article  PubMed  CAS  Google Scholar 

  38. Swart GW, Lunter PC, Kilsdonk JW, Kempen LC. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev. 2005;24:223–36.

    Article  PubMed  CAS  Google Scholar 

  39. Scala S, Ottaiano A, Ascierto PA, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 2005;11: 1835–41.

    Article  PubMed  CAS  Google Scholar 

  40. McCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL, Rimm DL, Kluger HM. HSP90 as a marker of progression in melanoma. Ann Oncol. 2008;19:590–4.

    Article  PubMed  CAS  Google Scholar 

  41. Duncan LM, Deeds J, Hunter J, et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res. 1998;58: 1515–20.

    PubMed  CAS  Google Scholar 

  42. Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, Zelger B. Metallothionein - overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br J Cancer. 2006;94:835–41.

    Article  PubMed  CAS  Google Scholar 

  43. Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F, Baehner FL, Simko J, Leong SP, Haqq C, Hauschild A, Schadendorf D, Miller 3rd JR, Sagebiel RW. A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res. 2009;15:6987–92.

    Article  PubMed  CAS  Google Scholar 

  44. Bakos RM, Maier T, Besch R, Mestel DS, Ruzicka T, Sturm RA, Berking C. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma. Exp Dermatol. 2010;19:e89–94.

    Article  PubMed  Google Scholar 

  45. Piras F, Perra MT, Murtas D, Minerba L, Floris C, Maxia C, Demurtas P, Ugalde J, Ribatti D, Sirigu P. The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep. 2010;23:17–24.

    PubMed  Google Scholar 

  46. Strizzi L, Postovit LM, Margaryan NV, Lipavsky A, Gadiot J, Blank C, Seftor RE, Seftor EA, Hendrix MJ. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol. 2009;4:67–78.

    Article  PubMed  CAS  Google Scholar 

  47. Murtas D, Piras F, Minerba L, Ugalde J, Floris C, Maxia C, Demurtas P, Perra MT, Sirigu P. Nuclear 8-hydroxy-2′-deoxyguanosine as survival biomarker in patients with cutaneous melanoma. Oncol Rep. 2010;23:329–35.

    PubMed  Google Scholar 

  48. Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, Miller 3rd JR, Sagebiel RW, Kashani-Sabet M. Osteopontin as a molecular prognostic marker for melanoma. Cancer. 2008;112:144–50.

    Article  PubMed  Google Scholar 

  49. Carvalho L, Lipay M, Belfort F, Santos I, Andrade J, Haddad A, Brunstein F, Ferreira L. Telomerase activity in prognostic histopathologic features of melanoma. J Plast Reconstr Aesthet Surg. 2006;59:961–8.

    Article  PubMed  Google Scholar 

  50. Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM, Rimm DL. Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol. 2009;27:5772–80.

    Article  PubMed  Google Scholar 

  51. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353: 2135–47.

    Article  PubMed  CAS  Google Scholar 

  52. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–6.

    Article  PubMed  CAS  Google Scholar 

  53. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008;5:e120.

    Article  PubMed  Google Scholar 

  54. Ugurel S, Schadendorf D, Pfoehler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res. 2006;12:5454–63.

    Article  PubMed  CAS  Google Scholar 

  55. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmüller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995; 31A:1898–902.

    Article  PubMed  CAS  Google Scholar 

  56. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol. 1998;138: 426–30.

    Article  PubMed  CAS  Google Scholar 

  57. Hauschild A, Engel G, Brenner W, Glaeser R, Moenig H, Henze E, Christophers E. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol. 1999;140:1065–71.

    Article  PubMed  CAS  Google Scholar 

  58. Krahn G, Kaskel P, Sander S, Waizenhofer PJ, Wortmann S, Leiter U, Peter RU. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001;21:1311–6.

    PubMed  CAS  Google Scholar 

  59. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer. 2003;97: 1737–45.

    Article  PubMed  CAS  Google Scholar 

  60. Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J, Martin R. Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res. 1989;49:5358–63.

    PubMed  CAS  Google Scholar 

  61. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res. 1994;54:5695–701.

    PubMed  CAS  Google Scholar 

  62. Bosserhoff AK, Kaufmann M, Kaluza B, et al. Melanoma-inhibitory activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 1997;57:3149–53.

    PubMed  CAS  Google Scholar 

  63. Stahlecker J, Gauger A, Bosserhoff A, Büttner R, Ring J, Hein R. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res. 2000;20:5041–4.

    PubMed  CAS  Google Scholar 

  64. Agrup P, Carstam R, Wittbjer A, Rorsman H, Rosengren E. Tyrosinase activity in serum from patients with malignant melanoma. Acta Derm Venereol. 1989;69:120–4.

    PubMed  CAS  Google Scholar 

  65. Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res. 1997;57:5073–6.

    PubMed  CAS  Google Scholar 

  66. Stoitchkov K, Letellier S, Garnier JP, et al. Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker. Melanoma Res. 2003;13:587–93.

    Article  PubMed  CAS  Google Scholar 

  67. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001;19:577–83.

    PubMed  CAS  Google Scholar 

  68. Hirai S, Kageshita T, Kimura T, et al. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res. 1997;7:58–62.

    Article  PubMed  CAS  Google Scholar 

  69. Vuoristo MS, Laine S, Huhtala H, et al. Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer. 2001;37:1629–34.

    Article  PubMed  CAS  Google Scholar 

  70. Franzke A, Probst-Kepper M, Buer J, et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer. 1998;78:40–5.

    Article  PubMed  CAS  Google Scholar 

  71. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res. 2005;11:5158–66.

    Article  PubMed  CAS  Google Scholar 

  72. Yoshino Y, Kageshita T, Nakajima M, Funakubo M, Ihn H. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and −2 in patients with malignant melanoma. J Dermatol. 2008;35:206–14.

    Article  PubMed  CAS  Google Scholar 

  73. Mouawad R, Benhammouda A, Rixe O, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res. 1996;2:1405–9.

    PubMed  CAS  Google Scholar 

  74. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 1995;5:67–8.

    Article  PubMed  CAS  Google Scholar 

  75. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest. 2001;19:239–47.

    Article  PubMed  CAS  Google Scholar 

  76. Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T, et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer. 2000;83:847–52.

    Article  PubMed  CAS  Google Scholar 

  77. Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H. Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer. 2002;100:580–5.

    Article  PubMed  CAS  Google Scholar 

  78. Westhoff U, Fox C, Otto FJ. Soluble HLA class I antigens in plasma of patients with malignant melanoma. Anticancer Res. 1998;18:3789–92.

    PubMed  CAS  Google Scholar 

  79. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993;72:3091–8.

    Article  PubMed  CAS  Google Scholar 

  80. Deichmann M, Kahle B, Moser K, Wacker J, Wust K. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer. 2004;91:699–702.

    PubMed  CAS  Google Scholar 

  81. Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer. 2005;117:825–30.

    Article  PubMed  CAS  Google Scholar 

  82. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res. 2001;7:1282–6.

    PubMed  CAS  Google Scholar 

  83. Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol. 2006;24:798–804.

    Article  PubMed  CAS  Google Scholar 

  84. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006;106:1130–9.

    Article  PubMed  CAS  Google Scholar 

  85. Vergilis IJ, Szarek M, Ferrone S, Reynolds SR. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol. 2005;125:526–31.

    Article  PubMed  CAS  Google Scholar 

  86. Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, Schadendorf D, Ugurel S. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res. 2009;15:5208–15.

    Article  PubMed  CAS  Google Scholar 

  87. Faries MB, Gupta RK, Ye X, Lee C, Yee R, Leopoldo Z, Essner R, Foshag LJ, Elashoff D, Morton DL. A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Invest. 2007;25:285–93.

    Article  PubMed  CAS  Google Scholar 

  88. Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, Ugurel S. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol. 2009;27: 2199–208.

    Article  PubMed  CAS  Google Scholar 

  89. Hahn S, Ugurel S, Hanschmann KM, Strobel H, Tondera C, Schadendorf D, Löwer J, Löwer R. Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. AIDS Res Hum Retroviruses. 2008;24: 717–23.

    Article  PubMed  CAS  Google Scholar 

  90. Persson L, Hårdemark HG, Gustafsson J, Rundström G, Mendel-Hartvig I, Esscher T, Påhlman S. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke. 1987;18: 911–8.

    Article  PubMed  CAS  Google Scholar 

  91. Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, Näher H. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999;17:1891–6.

    PubMed  CAS  Google Scholar 

  92. Jury CS, McAllister EJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol. 2000;143:269–74.

    Article  PubMed  CAS  Google Scholar 

  93. Acland K, Evans AV, Abraha H, Healy CM, Roblin P, Calonje E, Orchard G, Higgins E, Sherwood R, Russell-Jones R. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol. 2002;146:832–5.

    Article  PubMed  CAS  Google Scholar 

  94. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.

    Article  PubMed  Google Scholar 

  95. Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol. 2005;23:5088–93.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University Medical Center Mannheim, Mannheim, Germany

    Jochen Utikal M.D.

  2. Department of Dermatology, Medical University of Graz, Graz, Austria

    Jürgen C. Becker M.D., Ph.D. & Selma Ugurel M.D.

Authors
  1. Jochen Utikal M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jürgen C. Becker M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Selma Ugurel M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jürgen C. Becker M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Health Center, Department of Dermatology, University of Connecticut, Farmington, 06030, Connecticut, USA

    Michael J. Murphy

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Utikal, J., Becker, J.C., Ugurel, S. (2012). Diagnostic and Prognostic Biomarkers in Melanoma: Current State of Play. In: Murphy, M. (eds) Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. Current Clinical Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-60761-433-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-433-3_2

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60761-432-6

  • Online ISBN: 978-1-60761-433-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation